Pamidronic acid
- Generic Name
- Pamidronic acid
- Brand Names
- Pamisol
- Drug Type
- Small Molecule
- Chemical Formula
- C3H11NO7P2
- CAS Number
- 40391-99-9
- Unique Ingredient Identifier
- OYY3447OMC
- Background
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming more popular.
Pamidronic acid was granted FDA approval on 31 October 1991.
- Indication
Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases
Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention
- Conditions
- OsteopeniaOther Complications of Lung TransplantComplications of Heart-lung Transplant
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 56
- Registration Number
- NCT00164008
Bisphosphonate Therapy for Osteogenesis Imperfecta
- Conditions
- Osteogenesis ImperfectaOsteoporosisPaget Disease of Bone
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT00159419
Pamidronate Administration in Breast Cancer Patients With Bone Metastases
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 152
- Registration Number
- NCT00128297
- Locations
- 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00124605
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Osteopenia and Renal Osteodystrophy: Evaluation and Management
- Conditions
- OsteopeniaRenal Osteodystrophy
- First Posted Date
- 2005-04-15
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00108394
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
A Pilot Trial of Intravenous (IV) Pamidronate for Low Back Pain
- First Posted Date
- 2005-01-14
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 44
- Registration Number
- NCT00101790
- Locations
- 🇺🇸
The Mount Sinai Medical Center, New York, New York, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Hackensack Meridian Health
- Registration Number
- NCT00004906
- Locations
- 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
- Conditions
- Multiple Myeloma
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 20
- Registration Number
- NCT00083408
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 83
- Registration Number
- NCT00083382
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00033332
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸CCOP - Scott and White Hospital, Temple, Texas, United States
🇺🇸Veterans Affairs Medical Center - Madison, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.